Evidence map›Paper›PMID 25357204›Full record

ArticlePLoS genetics2014

Integrating functional data to prioritize causal variants in statistical fine-mapping studies.

Gleb Kichaev, Wen-Yun Yang, Sara Lindstrom, Farhad Hormozdiari, Eleazar Eskin, Alkes L Price, Peter Kraft, Bogdan Pasaniuc

Abstract read
In one paragraph

Article in PLoS genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 347 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
347citing papers in PubMed, 20 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

347 citing papers in PubMed, 20 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. A stop-gain variant inHGG advances · 2023
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

287 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gleb KichaevBioinformatics Interdepartmental Program, University of California Los Angeles, Los Angeles, California, United States of America.
Wen-Yun YangDepartment of Computer Science, University of California Los Angeles, Los Angeles, California, United States of America.
Sara LindstromProgram in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Farhad HormozdiariDepartment of Computer Science, University of California Los Angeles, Los Angeles, California, United States of America.
Eleazar EskinBioinformatics Interdepartmental Program, University of California Los Angeles, Los Angeles, California, United States of America; Department of Computer Science, University of California Los Angeles, Los Angeles, California, United States of America; Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Alkes L PriceProgram in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, Massachusetts, United States of America; Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Peter KraftProgram in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, Massachusetts, United States of America; Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Bogdan PasaniucBioinformatics Interdepartmental Program, University of California Los Angeles, Los Angeles, California, United States of America; Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.

Funding

STATISTICAL METHODS FOR GENE MAPPINGR01GM053275 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LANGE, KENNETH L · 1995 to 2019
$9.3M
Prioritizing follow-up of GWAS loci using genetic and functional annotation dataR21CA182821 · NCI · UNIVERSITY OF WASHINGTON · PI LINDSTROEM, SARA · 2014 to 2015
$395k
Metrics and methods for cross-population fine mappingR03CA162200 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PASANIUC, BOGDAN · 2012 to 2013
$149k
NCI NIH HHS R03 CA162200NCI NIH HHS R03-CA162200NCI NIH HHS R21 CA182821NCI NIH HHS R21-CA182821NIGMS NIH HHS R01 GM053275NIGMS NIH HHS R01-GM053275
6 · The paper itself

Abstract

Standard statistical approaches for prioritization of variants for functional testing in fine-mapping studies either use marginal association statistics or estimate posterior probabilities for variants to be causal under simplifying assumptions. Here, we present a probabilistic framework that integrates association strength with functional genomic annotation data to improve accuracy in selecting plausible causal variants for functional validation. A key feature of our approach is that it empirically estimates the contribution of each functional annotation to the trait of interest directly from summary association statistics while allowing for multiple causal variants at any risk locus. We devise efficient algorithms that estimate the parameters of our model across all risk loci to further increase performance. Using simulations starting from the 1000 Genomes data, we find that our framework consistently outperforms the current state-of-the-art fine-mapping methods, reducing the number of variants that need to be selected to capture 90% of the causal variants from an average of 13.3 to 10.4 SNPs per locus (as compared to the next-best performing strategy). Furthermore, we introduce a cost-to-benefit optimization framework for determining the number of variants to be followed up in functional assays and assess its performance using real and simulation data. We validate our findings using a large scale meta-analysis of four blood lipids traits and find that the relative probability for causality is increased for variants in exons and transcription start sites and decreased in repressed genomic regions at the risk loci of these traits. Using these highly predictive, trait-specific functional annotations, we estimate causality probabilities across all traits and variants, reducing the size of the 90% confidence set from an average of 17.5 to 13.5 variants per locus in this data.

Indexed as

AlgorithmsChromosome MappingGenome-Wide Association StudyHumansLinkage DisequilibriumModels, TheoreticalPolymorphism, Single Nucleotide

Identifiers

PMID25357204
PMCPMC4214605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.